Related Experiment Video
Updated: Jan 18, 2026

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Batatasin III alleviates slow transit constipation by regulating gut microbiota and inhibiting the NLRP3-IL-1β
Fangxu Yin1, ZiYing Jiang1, Yunbin Tong1
1Department of Pediatric Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Abstract:
Slow transit constipation (STC) is a functional gastrointestinal disorder characterized by impaired intestinal motility, inflammatory responses, and gut microbiota dysbiosis. Batatasin III, a natural stilbene compound, has been demonstrated to exhibit anti-inflammatory and neuroprotective properties; however, its role in STC remains unclear. In this study, a loperamide-induced STC mouse model was established and treated with low and high doses of Batatasin III. The therapeutic effects were evaluated through general phenotypic observation, small intestinal transit rate measurement, hematoxylin-eosin (HE) staining, enzyme-linked immunosorbent assay (ELISA), quantitative reverse transcription polymerase chain reaction (qRT-PCR), Western blotting, immunofluorescence, and 16S rRNA sequencing. Furthermore, Spearman correlation analysis was conducted to investigate the relationships between the gut microbiota and inflammatory cytokines and neurotransmitters. Batatasin III significantly improved fecal parameters and intestinal transit rate in mice, restored colonic tissue structure, and modulated levels of neurotransmitters such as 5-hydroxytryptamine (5-HT) and substance P (SP). Additionally, it inhibited activation of the NLRP3-IL-1β signaling pathway and reduced the expression of pro-inflammatory cytokines. Gut microbiota sequencing revealed an increase in beneficial bacteria such as Parabacteroides and Faecalibaculum, alongside a decreased abundance of the pro-inflammatory Rikenellaceae. These microbial changes were significantly correlated with both inflammatory markers and neurotransmitter levels. Batatasin III alleviates STC-related symptoms by modulating the gut microbiota and inhibiting the NLRP3-IL-1β inflammatory pathway. Its therapeutic effects may be mediated through the microbiota-gut-brain axis (MGBA), highlighting its potential value as a novel therapeutic agent for the treatment of slow transit constipation.
Related Concept Videos
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Irritable Bowel Syndrome III: Medical and Nursing Management
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Drugs Affecting GI Tract Motility: Other Laxatives
Osmotic or saline laxatives, like magnesium hydroxide or milk of...

